AQR Capital Management LLC trimmed its holdings in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 29.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 517,202 shares of the company's stock after selling 211,830 shares during the period. AQR Capital Management LLC owned 0.43% of 10x Genomics worth $7,427,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Barclays PLC grew its stake in 10x Genomics by 11.7% in the 3rd quarter. Barclays PLC now owns 602,536 shares of the company's stock valued at $13,605,000 after buying an additional 63,079 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of 10x Genomics by 355.0% during the third quarter. JPMorgan Chase & Co. now owns 355,488 shares of the company's stock worth $8,027,000 after purchasing an additional 277,355 shares during the period. Diversified Trust Co acquired a new stake in 10x Genomics during the 4th quarter worth approximately $511,000. Green Alpha Advisors LLC bought a new position in 10x Genomics during the 4th quarter worth $355,000. Finally, Assenagon Asset Management S.A. acquired a new stake in 10x Genomics in the 4th quarter worth about $26,308,000. 84.68% of the stock is currently owned by institutional investors.
Insider Buying and Selling at 10x Genomics
In related news, CEO Serge Saxonov sold 5,092 shares of 10x Genomics stock in a transaction on Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $56,368.44. Following the completion of the transaction, the chief executive officer now owns 879,482 shares of the company's stock, valued at $9,735,865.74. This trade represents a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Benjamin J. Hindson sold 4,573 shares of the company's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $50,623.11. Following the sale, the insider now directly owns 335,324 shares in the company, valued at $3,712,036.68. This trade represents a 1.35 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 9.39% of the company's stock.
10x Genomics Stock Performance
Shares of 10x Genomics stock traded up $0.24 on Friday, hitting $8.87. The stock had a trading volume of 7,825,567 shares, compared to its average volume of 2,323,145. The stock has a 50 day moving average of $8.95 and a 200 day moving average of $12.56. The firm has a market capitalization of $1.08 billion, a P/E ratio of -5.84 and a beta of 1.94. 10x Genomics, Inc. has a twelve month low of $6.78 and a twelve month high of $28.25.
10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. Equities analysts expect that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities analysts have commented on TXG shares. Canaccord Genuity Group lowered their price objective on 10x Genomics from $20.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th. JPMorgan Chase & Co. dropped their price target on 10x Genomics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday. Stifel Nicolaus reduced their price objective on shares of 10x Genomics from $21.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th. Leerink Partnrs cut shares of 10x Genomics from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 13th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of 10x Genomics in a research report on Saturday. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $18.62.
Get Our Latest Report on TXG
About 10x Genomics
(
Free Report)
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.
Featured Stories
Before you consider 10x Genomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 10x Genomics wasn't on the list.
While 10x Genomics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
